Send me real-time posts from this site at my email
Zacks

Rollins (ROL) to Post Q3 Earnings: What's in the Offing?

Rollins, Inc. ROL is scheduled to report third-quarter 2020 results on Oct 28, before the bell.

The company’s earnings beat the Zacks Consensus Estimate in the second quarter of 2020. The average trailing four-quarter surprise is 5.6%.

Expectations This Time Around

Acquisitions, customer growth and pricing are likely to have driven the company’s top line in the to-be-reported quarter, offsetting impacts of coronavirus-led general reduction in demand for services. The Zacks Consensus Estimate for revenues is pegged at $574.7 million, indicating 3.3% year-over-year growth. Rollins’ revenues were up 5.6% year over year in the second quarter of 2020.

The bottom line is likely to have been positively impacted by continued enhancements in routing and scheduling initiatives. With the consensus mark pegged at 23 cents, earnings are expected to increase 4.6% year over year. Earnings improved 9.5% year over year in the second quarter of 2020.

What Our Model Says

Our proven model does not conclusively predict an earnings beat for Rollins this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Rollins has an Earnings ESP of 0.00% and a Zacks Rank #3.

Rollins, Inc. Price and EPS Surprise

Stocks That Warrant a Look

Aptiv APTV has an Earnings ESP of +15.51% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.

Booz Allen Hamilton BAH has an Earnings ESP of +3.64% and a Zacks Rank #3.

Waste Connections WCN has an Earnings ESP of +0.32% and a Zacks Rank #3.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Waste Connections, Inc. (WCN): Free Stock Analysis Report
 
Booz Allen Hamilton Holding Corporation (BAH): Free Stock Analysis Report
 
Rollins, Inc. (ROL): Free Stock Analysis Report
 
Aptiv PLC (APTV): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue